Chemists stapled the gut hormone behind Ozempic into a sturdier shape, clipped a protein-destroying drug onto it, and used it to wipe out a target protein only inside cells that carry the hormone's receptor.
The result, reported online June 12 in Angewandte Chemie ↗, is what the authors call the first GLP-1-guided PROTAC. It is a chemistry proof of concept, run in cells rather than animals, but it tackles a problem that has kept a powerful class of drugs penned in.
The drug class that goes everywhere
PROTAC stands for proteolysis-targeting chimera. The idea is to destroy a disease protein rather than just block it. A PROTAC is a two-headed molecule: one head grabs the target protein, the other recruits the cell's own disposal machinery, and the target gets shredded and recycled. Blocking a protein is temporary and needs constant dosing. Destroying it is more like flipping a switch off.
The trouble is aim. A PROTAC that destroys a protein everywhere destroys it in healthy cells too, and there has been no clean way to send one to a single cell type. That is the gap this work goes after.
Turning the hormone into an address
GLP-1 ↗ is the body's own "I have eaten" hormone, the natural peptide that the Ozempic-class drugs imitate. Its receptor sits densely on pancreatic beta cells, the insulin-making cells, which are also unusually exposed to the bloodstream. That makes GLP-1 a plausible address label: a molecule that beta cells will recognize and pull inside.
The team first rebuilt GLP-1 to survive the job. Using a reaction they call tryptophan-mediated multicomponent Petasis stapling, they pinned the peptide into a more rigid helix. The stapled version held its shape better, bound the GLP-1 receptor harder than the natural peptide, and carried a spare chemical hook for attaching cargo. Onto that hook they clipped a degrader aimed at BRD4, a protein that helps switch genes on and a long-standing cancer target.
In cells that displayed the GLP-1 receptor, the conjugate did two things at once: it still acted as a GLP-1 agonist at the receptor, and it dragged its payload inside, where BRD4 levels dropped. The degradation tracked with the receptor, which is the whole point. The hormone was not the medicine. It was the delivery van.
What it is, and what it is not
This is early. The work shows selective degradation in receptor-positive cells in a dish, not a tumor shrinking in an animal, and BRD4 in beta cells is a model target chosen to prove the route, not a therapy anyone would deploy as written. A conjugate that has to retain receptor agonism while ferrying a payload also has to clear a long list of later hurdles: stability in blood, how much actually gets in, whether the GLP-1 signaling it triggers along the way is wanted.
But the logic travels. Most targeted-degradation programs hunt for cleverer degrader heads. This one keeps the head and solves the address instead, using a receptor that the entire GLP-1 drug industry has already mapped in detail. Peptides that bind a known receptor are a large and growing fraction of the field, and most are valued for what they do at the receptor. This is a reminder that the same binding can be repurposed as a doorway. The hormone gets the package to the right door. The package does the rest.